Milestones

• Mechanistic target of GLY-230 shown to induce changes in retinal cells associated with diabetic retinopathy

• GLY-230 corrects abnormalities of diabetic retinopathy in experimental diabetes

• GLY-230 shows efficacy in Phase 2 clinical trial

• GLY-230 shows positive results in experimental model of Alzheimer’s disease

• GLY-220 prevents changes of macrovascular disease in preclinical studies

• Humanized A717 mAb and single-chain A717 successfully developed.